BioNotebook: Targacept, AcelRx/Grunenthal, Retrophin/Transcept, AmpliPhi
This article was originally published in Scrip
Executive Summary
Targacept sinks on another failure; AcelRx signs EU Zalviso deal; Retrophin drops Transcept bid; and AmpliPhi nets $16.9m in stock sale.
You may also be interested in...
AmpliPhi Advances Phage In Clinic To Address Microbial Infections
Emerging Company Profile: Using cocktails of bacteriophages to attack bacterial infections, San Diego-based AmpliPhi has made progress in Phase I studies for its lead program. CEO Scott Salka explains to Mike Ward how he is looking to secure sufficient capital to support the Phase II development of AmpliPhi's lead program against chronic rhinosinusitis while advancing other product candidates.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.